Alterations in lipid profiles in HIV-infected patients treated with inhibitor therapy are not influenced by diet

Nutrition in Clinical Practice

Volumn 20, Issue 6, 2005, Pages 668-673

  Wanke, Christine ^a,b   Gerrior, Jül ^a   Hendricks, Kristy ^a   McNamara, Judith ^c   Schaefer, Ernest ^c,d  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY   (United States)

^d TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHOLESTEROL; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LAMIVUDINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MINERAL; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RETINOL; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRACE ELEMENT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VIRUS RNA; VITAMIN; ZIDOVUDINE;

ADULT; ARTICLE; BIOELECTRICAL IMPEDANCE ANALYSIS; BLOOD SAMPLING; BODY COMPOSITION; BODY FAT; BODY MASS; CALORIC INTAKE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIETARY INTAKE; DRUG UTILIZATION; EVALUATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MALE; TECHNIQUE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 29044447026     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/0115426505020006668     Document Type: Article

References (21)

1. Lo J, Mulligan K, Tai V, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet. 1998;35:867-870.
2. Carr A, Samaras K, Chisolm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351:1881-1883.
3. Mulligan K, Grunfeld C, Tai V, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J AIDS. 2000;23:35-43.
4. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
5. Miller K, Jones E, Yanovski J, Shankar R, Feuerstien I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 1998;351:871-875.
6. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13:F63-F70.
7. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS. 1997;11:938-939.
8. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045-1052.
9. Forrester JE, Spiegelman D, Woods MN, Knox TA, Fauntleroy JM, Gorbach SL. Weight loss and body composition in cohort of HIV positive men and women. Public Health Nutr. 2001;4:743-747.
10. Lohman TG, Roche AF, Martorell R, eds. Anthropometric Standardization Reference Manual. Champagne, IL: Human Kinetics Books; 1988.
11. Lukaski HC, Johnson PE, Bolonchuk WW, Lykken GI. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr. 1985;41:810-817.
12. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta. 1987;166:1-8.
13. Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels: the Framingham Offspring Study. Circulation. 1993;87:1135-1141.
14. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS. 2000;14:51-57.
15. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors: the Swiss HIV Cohort Study. Circulation. 1999;100:700-705.
16. Grunfeld C, Tien P. Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clin Infect Dis. 2003;37(suppl 2):S43-S46.
17. Van der Valk M, Kastelein JJ, Murphy RL, et al. The Atlantic Study Team: tevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001;15:2407-2414.
18. Krauss RM, Eckel RH, Howard B, et al. AHA dietary guidelines revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation. 2000;102:2284-2299.
19. Dube MP, Steinberg D, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV) infected adults receiving antiretroviral therapy, recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627.
20. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids: A Report of the Panel on Dietary Antioxidants and Related Compounds, Subcommittees on Upper Reference Levels of Nutrients and of Interpretation and Use of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. National Academy of Sciences, Washington, DC; 2000.
21. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline: A Report of the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and Its Panel on Folate, Other B Vitamins, and Choline and Subcommittee on Upper Reference Levels of Nutrients, Food and Nutrition Board, Institute of Medicine. National Academy of Sciences, Washington, DC; 2000.